An analysis by consumer website GoodRx concluded that the price people pay for generic drugs at the pharmacy varies greatly based on where they live.
An analysis by consumer website GoodRx concluded that the price people pay for generic drugs at the pharmacy varies greatly based on where they live. The study looked at 500 commonly used drugs in 30 of the most populated American cities over the last 12 months, ending April 2018. Researchers examined the average cash price of the drug at a pharmacy. Although many people have insurance coverage for prescriptions or discounts and don’t pay cash, more people are paying larger shares for prescriptions out of pocket. The results are based on a representative sample of US prescription fills (not fills using GoodRx) and comes from several sources including pharmacies and insurers.
The most expensive cities in the country for drugs were New York City (20% more than the national average) and Los Angeles and San Francisco (12.6% and 9.8% higher, respectively). Notably, prices in similar cities in the same state varied widely; in Columbus, Ohio, for example, prices were nearly 22% below the national average. Conversely, Cleveland’s prices were 2.5% above the national average and the 2 cities are only 150 miles apart. The cities with the least expensive drugs are Columbus, Ohio; Atlanta, Georgia (18.6% below); and Houston, Texas (17.4% below).
“This data highlights the nonsensical and variable nature of drug pricing,” the report notes. Cost-of-living differences don’t explain the full story because, for instance, drug prices in Washington, DC, where the cost of living is relatively high, are 9.0% lower than the national average. Raleigh, North Carolina, which has a lower cost of living, has higher prescription drug costs (4.3% higher than the national average).
What GoodRx calls the “Big Box Effect” may play a part in drug price variability because many larger big box stores offer popular brand and generic drugs at a cheaper rate, often $4 for a 30-day supply and $9 for a 90-day supply. Some states have more big box stores, giving residents more opportunities to save on medications.
Retail markup also plays a role in generic drug price disparities because some pharmacies claim a higher margin to support their business and these pharmacies are distributed unevenly throughout a state.
An example of the price differences for the same generic drug across the country are reflected in the comparison of prices for metformin, which treats type 2 diabetes, and the flu medication Tamiflu:
Metformin
Birmingham: $43.00
Boston: $28.57
Columbus: $11.16
New York: $66.23
San Francisco: $49.36
Tamiflu
Birmingham: $197.48
Boston: $185.46
Columbus: $189.61
New York: $155.46
San Francisco: $201.61
While many factors contribute to the differences in generic drug prices, much can still be “chalked up to the ‘drug prices make no sense’ theory,” said Thomas Goetz, GoodRx’s chief of research. Leigh Purvis, AARP's public policy institute director, noted that price variations are not just from city to city, even pharmacies on the same block can sell drugs at very different prices.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.